Adrenal adenomata displaying mild autonomous cortisol secretion: a service evaluation of cardiometabolic profile routinely screened patients.

IF 1.1 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Cardiovascular Endocrinology & Metabolism Pub Date : 2026-03-02 eCollection Date: 2026-03-01 DOI:10.1097/XCE.0000000000000357
Adrian H Heald, Callum Stables, Sarah Jamil, Waseem Majeed, Sangeeth Veluchamy, Rupinder Kochhar, Akheel Syed, Rajshekhar Mudaliar, Fahmy Hanna, David Marshall, Ian Laing, Mark Livingston, Anthony A Fryer, Adhithya Sankar, Brian Keevil
{"title":"Adrenal adenomata displaying mild autonomous cortisol secretion: a service evaluation of cardiometabolic profile routinely screened patients.","authors":"Adrian H Heald, Callum Stables, Sarah Jamil, Waseem Majeed, Sangeeth Veluchamy, Rupinder Kochhar, Akheel Syed, Rajshekhar Mudaliar, Fahmy Hanna, David Marshall, Ian Laing, Mark Livingston, Anthony A Fryer, Adhithya Sankar, Brian Keevil","doi":"10.1097/XCE.0000000000000357","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>A proportion of adrenal adenomata exhibit autonomous cortisol secretion, now termed mild autonomous cortisol secretion (MACS), as defined by post-1mg overnight dexamethasone suppression test (ONDST) cortisol 51-137 nmol/l. Here, we characterized the cardiometabolic profile of MACS.</p><p><strong>Methods: </strong>Clinical records of 98 individuals with adrenal adenomata were examined. Subcategorization into MACS1 (ONDST cortisol of 50-137 nmol/l) and MACS2 (ONDST cortisol of >137 nmol/l was created to take account of individuals with ONDST cortisol of more than 137 nmol/l and no diagnosis of Cushing's syndrome.</p><p><strong>Results: </strong>Diagnosis of MACS1 associated with a higher diagnosis rate of cardiovascular disease (CVD) (17.7% MACS1) vs. non-MACS = nonfunctioning adenoma (NFA) (3.7%) (<i>P</i> = 0.009) and higher rates of prescription of lipid-lowering agents (51.6%) vs. (29.6%) (<i>P</i> = 0.01). ONDST cortisol levels in MACS1 patients correlated with a more adverse lipid profile (for higher low-density lipoprotein cholesterol, <i>r</i> <sup>2</sup> = 0.404, <i>P</i> = 0.007; high-density lipoprotein cholesterol <i>r</i> <sup>2</sup> = -0.346, <i>P</i> = 0.023; for higher serum triglycerides <i>r</i> <sup>2</sup> = 0.282, <i>P</i> = 0.02) in spite of higher rates of statin prescribing. There was a gradient of increasing numbers of antihypertensives prescribed, going from non-MACS NFA to MACS1 to MACS2. Dunn's post hoc analysis indicated an overall more adverse lipid profile in MACS1.</p><p><strong>Conclusion: </strong>The positive direction of associations between serum cortisol and lipid measures highlights that MACS carries a metabolically adverse lipid profile. Diagnosis of MACS was associated with a higher diagnosis rate of CVD and appropriately higher rates of prescription of lipid-lowering agents and a greater number of antihypertensive agents prescribed. The question remains about whether a specific directed treatment of MACS should be offered beyond risk-factor-mitigating management.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"15 1","pages":"e00357"},"PeriodicalIF":1.1000,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12956158/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Endocrinology & Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/XCE.0000000000000357","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: A proportion of adrenal adenomata exhibit autonomous cortisol secretion, now termed mild autonomous cortisol secretion (MACS), as defined by post-1mg overnight dexamethasone suppression test (ONDST) cortisol 51-137 nmol/l. Here, we characterized the cardiometabolic profile of MACS.

Methods: Clinical records of 98 individuals with adrenal adenomata were examined. Subcategorization into MACS1 (ONDST cortisol of 50-137 nmol/l) and MACS2 (ONDST cortisol of >137 nmol/l was created to take account of individuals with ONDST cortisol of more than 137 nmol/l and no diagnosis of Cushing's syndrome.

Results: Diagnosis of MACS1 associated with a higher diagnosis rate of cardiovascular disease (CVD) (17.7% MACS1) vs. non-MACS = nonfunctioning adenoma (NFA) (3.7%) (P = 0.009) and higher rates of prescription of lipid-lowering agents (51.6%) vs. (29.6%) (P = 0.01). ONDST cortisol levels in MACS1 patients correlated with a more adverse lipid profile (for higher low-density lipoprotein cholesterol, r 2 = 0.404, P = 0.007; high-density lipoprotein cholesterol r 2 = -0.346, P = 0.023; for higher serum triglycerides r 2 = 0.282, P = 0.02) in spite of higher rates of statin prescribing. There was a gradient of increasing numbers of antihypertensives prescribed, going from non-MACS NFA to MACS1 to MACS2. Dunn's post hoc analysis indicated an overall more adverse lipid profile in MACS1.

Conclusion: The positive direction of associations between serum cortisol and lipid measures highlights that MACS carries a metabolically adverse lipid profile. Diagnosis of MACS was associated with a higher diagnosis rate of CVD and appropriately higher rates of prescription of lipid-lowering agents and a greater number of antihypertensive agents prescribed. The question remains about whether a specific directed treatment of MACS should be offered beyond risk-factor-mitigating management.

显示轻度自主皮质醇分泌的肾上腺腺瘤:常规筛查患者心脏代谢概况的服务评估。
部分肾上腺腺瘤表现出自主皮质醇分泌,现在称为轻度自主皮质醇分泌(MACS),根据1mg后地塞米松抑制试验(ONDST)皮质醇51-137 nmol/l来定义。在这里,我们描述了MACS的心脏代谢特征。方法:对98例肾上腺腺瘤患者的临床资料进行分析。考虑到ONDST皮质醇高于137 nmol/l且未诊断为库欣综合征的个体,将其划分为MACS1 (ONDST皮质醇为50-137 nmol/l)和MACS2 (ONDST皮质醇为bb0 -137 nmol/l)。结果:MACS1诊断与心血管疾病(CVD)诊断率(17.7% MACS1)高于非macs =无功能腺瘤(NFA) (3.7%) (P = 0.009)和降脂药处方率(51.6%)高于(29.6%)(P = 0.01)相关。MACS1患者的ONDST皮质醇水平与更不利的脂质谱相关(低密度脂蛋白胆固醇较高,r 2 = 0.404, P = 0.007;高密度脂蛋白胆固醇r 2 = -0.346, P = 0.023;血清甘油三酯较高,r 2 = 0.282, P = 0.02),尽管他汀类药物处方率较高。从非macs NFA到MACS1再到MACS2,降压药处方数量呈梯度增加。Dunn的事后分析显示MACS1总体上更不利的脂质谱。结论:血清皮质醇和脂质测量呈正相关,表明MACS具有代谢不良的脂质特征。MACS的诊断与较高的CVD诊断率、适当较高的降脂药物处方率和较多的抗高血压药物处方有关。问题仍然是,除了风险因素缓解管理之外,是否应该提供针对MACS的特定定向治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cardiovascular Endocrinology & Metabolism
Cardiovascular Endocrinology & Metabolism CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
5.60
自引率
0.00%
发文量
24
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书